Fig. 1 · Structure
Documents & Downloads
Methyl lucidenate D
EBV-EA Inhibitor
Methyl lucidenate D is a selective inhibitor of Epstein-Barr virus early antigen (EBV-EA) activation, exhibiting an IC50 value of 290 mol ratio/32 pmol TPA. This compound demonstrates potential anti-tumor-promoting activity by inhibiting TPA-induced EBV-EA activation while preserving Raji cell viability at effective concentrations (70%). Methyl lucidenate D is applicable in cancer chemoprevention research, providing valuable insights into therapeutic strategies targeting viral influences in tumorigenesis.
In Stock
Free Aliquoting for Your Order
Tell us your preferred amount per vial. We’ll confirm the options.
Specifications
| Manufacturer | Adooq Bioscience |
|---|---|
| Actions | Inhibitor |
| CAS Number | 98665-09-9 |
| Applications | EBV-EA Inhibitor |
| Formula | C30H40O8 |
| Molecular Weight | 528.63 |
| SMILES | C[C@@]12[C@](C3=C([C@@]4([C@@](C(C)(C(CC4)=O)C)([H])CC3=O)C)C([C@H]1OC(C)=O)=O)(C(C[C@]2([H])[C@H](C)CCC(OC)=O)=O)C |
Storage & Solubility
In Vitro Solubility
Reported Solubility
No reported solubility data are available for this product.
Preparing Stock Solutions
| Concentration | |
|---|---|
Values use four significant digits. Prepare to the final solution volume; this is not the volume of solvent to add.
Stock preparation is unavailable for this product molecular weight.
Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.
Storage
Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.